NasdaqGM:MSON

Stock Analysis Report

Executive Summary

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally.


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Misonix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MSON's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.7%

MSON

-1.3%

US Medical Equipment

-1.1%

US Market


1 Year Return

-19.7%

MSON

19.4%

US Medical Equipment

17.8%

US Market

Return vs Industry: MSON underperformed the US Medical Equipment industry which returned 19.6% over the past year.

Return vs Market: MSON underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

MSONIndustryMarket
7 Day-2.7%-1.3%-1.1%
30 Day-13.4%0.02%1.5%
90 Day-18.6%5.5%6.6%
1 Year-19.7%-19.7%20.3%19.4%20.2%17.8%
3 Year62.1%62.1%79.2%74.2%47.5%38.1%
5 Year32.0%32.0%114.6%92.0%71.2%52.4%

Price Volatility Vs. Market

How volatile is Misonix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Misonix undervalued compared to its fair value and its price relative to the market?

2.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MSON's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MSON is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MSON is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MSON's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MSON is good value based on its PB Ratio (2x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Misonix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

74.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MSON is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: MSON is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MSON's is expected to become profitable in the next 3 years.

Revenue vs Market: MSON's revenue (24.8% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: MSON's revenue (24.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MSON's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Misonix performed over the past 5 years?

-57.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MSON is currently unprofitable.

Growing Profit Margin: MSON is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MSON is unprofitable, and losses have increased over the past 5 years at a rate of -57.3% per year.

Accelerating Growth: Unable to compare MSON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MSON is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).


Return on Equity

High ROE: MSON has a negative Return on Equity (-5.66%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Misonix's financial position?


Financial Position Analysis

Short Term Liabilities: MSON's short term assets ($40.2M) exceed its short term liabilities ($11.4M).

Long Term Liabilities: MSON's short term assets ($40.2M) exceed its long term liabilities ($40.1M).


Debt to Equity History and Analysis

Debt Level: MSON's debt to equity ratio (30.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MSON's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: MSON has a low level of unsold assets or inventory.

Debt Coverage by Assets: MSON's debt is covered by short term assets (assets are 1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MSON has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MSON has less than a year of cash runway if free cash flow continues to reduce at historical rates of -54.2% each year


Next Steps

Dividend

What is Misonix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MSON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MSON's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MSON's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MSON's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MSON's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Stavros Vizirgianakis (49yo)

3.2yrs

Tenure

US$554,153

Compensation

Mr. Stavros George Vizirgianakis, B.Com., has been the Chief Executive Officer of Misonix, Inc. since December 19, 2016 and served as it's President until September 2019. Mr. Vizirgianakis served as an Int ...


CEO Compensation Analysis

Compensation vs Market: Stavros's total compensation ($USD554.15K) is below average for companies of similar size in the US market ($USD1.11M).

Compensation vs Earnings: Stavros's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Stavros Vizirgianakis
CEO & Director3.2yrsUS$554.15k9.45% $27.4m
Joseph Dwyer
CFO, Treasurer & Secretary3.4yrsUS$821.87k0.015% $44.2k
Sharon Klugewicz
Chief Operating Officer0.9yrsUS$814.88k0.0034% $9.9k
Robert Ludecker
Senior Vice President of Global Sales & Marketing4.8yrsUS$695.82k0.063% $183.7k
Allan Staley
President0.4yrsno data1.36% $4.0m
Linwood Staub
Senior Vice President of Sales0.4yrsno datano data

2.0yrs

Average Tenure

51.5yo

Average Age

Experienced Management: MSON's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stavros Vizirgianakis
CEO & Director3.2yrsUS$554.15k9.45% $27.4m
Michael Koby
Independent Director0.4yrsno datano data
Thomas Patton
Independent Director5.1yrsUS$167.72k0.029% $83.5k
Paul LaViolette
Chairman of the Board0.3yrsno datano data
Gwendolyn Watanabe
Independent Director1.6yrsUS$191.01kno data

1.6yrs

Average Tenure

52yo

Average Age

Experienced Board: MSON's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.


Top Shareholders

Company Information

Misonix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Misonix, Inc.
  • Ticker: MSON
  • Exchange: NasdaqGM
  • Founded: 1959
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$289.917m
  • Shares outstanding: 17.36m
  • Website: https://www.misonix.com

Number of Employees


Location

  • Misonix, Inc.
  • 1938 New Highway
  • Farmingdale
  • New York
  • 11735
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MSONNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1992
MX9DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992

Biography

Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company’s products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:29
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.